Fig. 4

RORγt agonist 8-074 promotes CD8⁺ T and reduces Treg tumor infiltration in the LLC model. a Flow cytometry analysis of TIICs from LLC tumor-bearing mice in Fig. 3a, vehicle group and 8-074 (50 mg/kg) group. Mice with established LLC tumors were treated with vehicle or 8-074 (50 mg/kg) QD for 14 days. The percentage of CD45⁺ cells in the tumor was shown. The proportion of IL-17A⁺ and CTL cells among the CD3⁺ cell populations is also shown. b Statistical results of Flow Cytometry (FCM) analysis for CTL and IL-17A⁺ cells among CD3⁺ population in LLC and MC38 tumor. *P < 0.05, **P < 0.01, and ****P < 0.0001. c Statistical results of the FCM analysis for the CD45⁺ cells in the LLC tumor population. A student’s t-test was used for the statistical test (N = 5 per group, **P < 0.01). d Cumulative graph of the mean tumor size per group after CD8⁺ T cell depletion. **P < 0.01 by 2-way ANOVA. For CD8⁺ T cell depletion, mice were injected i.p. with 400 μg of anti-CD8α (YTS 169.4; BioXCell) one day before and dose per week after anti-PD-1 treatment. e CD8⁺ T cell populations of tumors from mice each group (**P < 0.01, and ***P < 0.001). f The percentage of CD45⁺ cells in the tumor and the proportion of CD8⁺ T and Treg among the CD3⁺ populations are shown. The Student’s t-test was used for the statistical test. Data represent mean ± SD of biological quadruplicates. Experiments were repeated three times with consistent results